This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.
Edwards Lifesciences' (EW) Global Sales Robust Amid Cost Woes
by Zacks Equity Research
Edwards Lifesciences (EW) is registering robust HemoSphere sales in the United States.
PerkinElmer (PKI) Boosts In Vivo Imaging Profile With New System
by Zacks Equity Research
PerkinElmer's (PKI) launch of the Vega imaging system is likely to help the company expand its in vivo imaging portfolio.
PerkinElmer's (PKI) New Assay Kits to Detect CHO HCP Impurities
by Zacks Equity Research
PerkinElmer (PKI) launches ready-to-use HTRF and AlphaLISA no-wash assay kits to quickly identify and quantify CHO HCP impurities.
Catalent's (CTLT) Latest Buyout to Expand Its Global Footprint
by Zacks Equity Research
Catalent's (CTLT) latest acquisition is likely to significantly enhance its global Biologics business.
Baxter's (BAX) ST Set Receives FDA Nod, to Boost Patient Outcome
by Zacks Equity Research
Baxter's (BAX) ST Set is expected to improve treatments in an acute care environment.
Edwards Lifesciences (EW) Stock Moves -0.05%: What You Should Know
by Zacks Equity Research
In the latest trading session, Edwards Lifesciences (EW) closed at $120.22, marking a -0.05% move from the previous day.
HOLX vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Shockwave Medical's (SWAV) New Launch to Lower IVL Treatment Time
by Zacks Equity Research
Shockwave Medical's (SWAV) latest global commercial launch is expected to serve a more diverse patient pool.
DexCom's (DXCM) Upcoming Launch to Boost Diabetes Management
by Zacks Equity Research
DexCom's (DXCM) upcoming launch of Dexcom ONE CGM can help people in the U.K. to manage diabetes.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.
Strength Seen in Alphatec (ATEC): Can Its 12.1% Jump Turn into More Strength?
by Zacks Equity Research
Alphatec (ATEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Edwards Lifesciences (EW) Gets FDA Nod for MITRIS RESILIA Valve
by Zacks Equity Research
Edwards Lifesciences' (EW) MITRIS RESILIA valve has been designed to resemble the appearance and function of the native mitral valve.
Edwards Lifesciences (EW) Up 7.5% Since Q4 Earnings Release
by Zacks Equity Research
Edwards Lifesciences' (EW) stock rallies on impressive fourth-quarter performance and bullish 2022 guidance.
The Zacks Analyst Blog Highlights Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences
by Zacks Equity Research
Visa, Novartis, Deere & Company, Airbnb, and Edwards Lifesciences have been included in this Analyst Blog.
Top Stock Reports for Visa, Novartis & Deere
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Novartis AG (NVS), and Deere & Company (DE).
Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Delcath Systems, Inc. (DCTH) delivered earnings and revenue surprises of 25.81% and 285.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences' (EW) robust segmental performance and growing product uptake.
Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Edwards Lifesciences (EW) closed at $102.25, marking a -1.16% move from the previous day.
Why Edwards Lifesciences (EW) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Edwards Lifesciences (EW) Stock Moves -0.68%: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed at $111.61 in the latest trading session, marking a -0.68% move from the prior day.
Why Is Edwards Lifesciences (EW) Up 7.5% Since Last Earnings Report?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards Lifesciences (EW) Stock Moves -0.58%: What You Should Know
by Zacks Equity Research
Edwards Lifesciences (EW) closed the most recent trading day at $105.33, moving -0.58% from the previous trading session.
Here's Why You Should Retain Edwards Lifesciences (EW) Stock
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on continued strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system.